Andrew Crenshaw has direct oversight of all Q2 Solutions CDx engagements as well as serving as the primary liaison for CDx to the Q2 Solutions parent organizations. Previously, he was senior director of strategy and operations excellence for Q2 Solutions, where he was responsible for multiple company-wide initiatives including the buildout of NGS capability in Q2 Solutions Beijing facility. Andrew has more than 18 years of experience in the clinical and biomedical research industry and has broad experience in translating strategy into operational activities, performance and relationship management, and continuous improvement. He served as genomics laboratory head in the next-gen diagnostic group in Novartis Institute for Biomedical Research (NIBR). Andrew was director of array & expression operations and development at the Broad Institute of MIT and Harvard, and has held various other operational management roles at the Broad Institute. Andrew received a BS in Microbiology, North Carolina State University and an MS in Biotechnology Studies at the University of Maryland University College.